Monopar Therapeutics — Director's Dealing 2018

Jan 8, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Monopar Therapeutics (NONE)
CIK: 0001645469
Period of Report: 2018-01-08

Reporting Person: Anderson Raymond (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	1000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock options	$6.00		Common stock (21024)		Direct

Footnotes

F1: Reflects the issuance of options to purchase up to 21,024 shares of common stock granted to Mr. Anderson on September 18, 2017 for his services as a director of Monopar Therapeutics. The options will vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter. The options each expire on September 17, 2027.